Related Experiment Video
Updated: Mar 12, 2026
Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
Published on: January 22, 2014
MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimer's Disease
Theresa A Lusardi1, Jay I Phillips2, Jack T Wiedrick3
1Computational Biology Program, Oregon Health & Science University, Portland, OR, USA.
Background:
Currently available biomarkers of Alzheimer's disease (AD) include cerebrospinal fluid (CSF) protein analysis and amyloid PET imaging, each of which has limitations. The discovery of extracellular microRNAs (miRNAs) in CSF raises the possibility that miRNA may serve as novel biomarkers of AD.
Objective:
Investigate miRNAs in CSF obtained from living donors as biomarkers for AD.
Methods:
We profiled miRNAs in CSF from 50 AD patients and 49 controls using TaqMan® arrays. Replicate studies performed on a subset of 32 of the original CSF samples verified 20 high confidence miRNAs. Stringent data analysis using a four-step statistical selection process including log-rank and receiver operating characteristic (ROC) tests, followed by random forest tests, identified 16 additional miRNAs that discriminate AD from controls. Multimarker modeling evaluated linear combinations of these miRNAs via best-subsets logistic regression, and computed area under the ROC (AUC) curve ascertained classification performance. The influence of ApoE genotype on miRNA biomarker performance was also evaluated.
Results:
We discovered 36 miRNAs that discriminate AD from control CSF. 20 of these retested in replicate studies verified differential expression between AD and controls. Stringent statistical analysis also identified these 20 miRNAs, and 16 additional miRNA candidates. Top-performing linear combinations of 3 and 4 miRNAs have AUC of 0.80-0.82. Addition of ApoE genotype to the model improved performance, i.e., AUC of 3 miRNA plus ApoE4 improves to 0.84.
Conclusions:
CSF miRNAs can discriminate AD from controls. Combining miRNAs improves sensitivity and specificity of biomarker performance, and adding ApoE genotype improves classification.
Insights
Cerebrospinal fluid microRNAs (miRNAs) show promise as Alzheimer's disease (AD) biomarkers. Combining specific miRNAs and ApoE genotype significantly improves diagnostic accuracy for AD detection.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Genetics
Background:
- Current Alzheimer's disease (AD) biomarkers like CSF proteins and PET imaging have limitations.
- Extracellular microRNAs (miRNAs) in cerebrospinal fluid (CSF) present a potential avenue for novel AD biomarker development.
Purpose of the Study:
- To investigate the utility of miRNAs in CSF as diagnostic biomarkers for Alzheimer's disease (AD).
- To evaluate the combined diagnostic performance of miRNA panels and ApoE genotype in AD detection.
Main Methods:
- MicroRNA profiling of CSF samples from AD patients and controls using TaqMan® arrays.
- Rigorous statistical analysis, including ROC and random forest tests, to identify discriminating miRNAs.
- Multimarker logistic regression modeling and evaluation of ApoE genotype influence on biomarker performance.
Main Results:
- Identified 36 miRNAs differentially expressed in CSF between AD patients and controls.
- Verified 20 high-confidence miRNAs through replicate studies.
- Achieved AUC values of 0.80-0.82 with 3-4 miRNA combinations, improved to 0.84 with ApoE4 genotype inclusion.
Conclusions:
- CSF miRNAs effectively discriminate between AD and control individuals.
- Combining multiple miRNAs enhances diagnostic sensitivity and specificity.
- Incorporating ApoE genotype further refines the classification accuracy for AD.
